Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Ikaros integrates endocrine and immune system development
Shereen Ezzat, … , Philippe Poussier, Sylvia L. Asa
Shereen Ezzat, … , Philippe Poussier, Sylvia L. Asa
Published April 1, 2005
Citation Information: J Clin Invest. 2005;115(4):1021-1029. https://doi.org/10.1172/JCI22486.
View: Text | PDF
Article Development

Ikaros integrates endocrine and immune system development

  • Text
  • PDF
Abstract

Ikaros transcription factors are essential regulators of lymphopoiesis and the development of the immune system. We now show that Ikaros is expressed in hormone-producing pituitary corticomelanotroph cells, where it binds the proopiomelanocortin promoter and regulates endogenous gene expression. Loss of Ikaros in vivo results in contraction of the pituitary corticomelanotroph population, reduced circulating adrenocorticotrophic hormone levels, and adrenal glucocorticoid insufficiency. While hemopoietic reconstitution failed to correct this hormonal deficit, the phenotype of reduced body weight and diminished survival was rescued by systemic glucocorticoid-hormone administration. Given the established immunomodulatory properties of glucocorticoid hormones, these findings reveal a novel role for Ikaros in orchestrating immune-endocrine development and function.

Authors

Shereen Ezzat, Rene Mader, ShunJiang Yu, Terry Ning, Philippe Poussier, Sylvia L. Asa

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Loss of Ikaros impairs pituitary corticomelanotroph development and ACTH...
Loss of Ikaros impairs pituitary corticomelanotroph development and ACTH expression. (A) The pituitaries of Ikaros-null mice (KO) at E17.5 were compared with age-matched controls from heterozygous (HET) and wild-type littermates as indicated. The sections were taken from the midline of the gland and include the sphenoid bone (S) in the midline below the gland. Note the normal onset and distribution of the corticomelanotroph-specific Tpit factor (upper panels) but reduced ACTH reactivity (lower panels) in heterozygous mice and near complete absence of ACTH in homozygous mice. (B) By 1 week of age, immunocytochemical examination reveals persistent loss of ACTH reactivity in the pituitary of Ikaros-null mice compared with wild-type control littermates. The heterozygous (HET) animals also showed loss of ACTH immunoreactivity, but the glands were larger than those of homozygous animals, and the striking loss involved the intermediate lobe (arrows) that is separated from the anterior lobe by the residual Rathke’s cleft (*) in the mid-portion of the gland. Original magnification, ×63.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts